Skip to main content

Caliper Enters Deal to Bring Diagnostic Product to Market

SAN FRANCISCO, Dec. 17 - Caliper Technologies has entered into a deal with Bacterial BarCodes to develop and co-distribute a clinical diagnostic system to detect and diagnose invasive bacterial infections, the companies said on Monday.


It is the first commercial diagnostics deal for Mountain View, Calif.-based Caliper, according to the company.


In the agreement, Caliper will combine its LabChip DNA analysis reagents and chips with Bacterial BarCodes' rep-PCR reagents in a diagnostic kit to be sold by Houston, Texas-based Bacterial BarCodes. Kit customers will have access to Bacterial BarCodes' database of bacterial fingerprints. The instruments that process the kit's chips will be marketed and sold by Caliper.


Financial details of the agreement were not disclosed.


"This collaboration with Bacterial BarCodes marks Caliper's entry into the diagnostics field, a large and growing potential market for our LabChip products," said Dan Kisner, CEO of Caliper. "Caliper intends to pursue additional strategic commercial alliances with the goal of enabling other innovative market leaders to incorporate LabChip capabilities into their product development and commercialization programs."


Bacterial BarCodes is a spin-off company of BCM Technologies, a venture development subsidiary of Baylor College of Medicine.

The Scan

Gap in COVAX Doses

BBC News reports that COVAX is experiencing a vaccine shortfall, as the Serum Institute of India has paused exports.

Sanofi, GSK Report Promising Results

The Wall Street Journal reports that the candidate SARS-CoV-2 vaccine from Sanofi and GlaxoSmithKline has had encouraging early results.

Influence of Luck

The New York Times examines how the US avoided variant-fueled increases in COVID-19 cases.

PLOS Papers on Retina GWAS, Hantaan Virus, COVID-19 Phenome-Wide Association Study

In PLOS this week: genome-wide association study of retinal morphology, analysis of hantaan virus found in a mouse, and more.